Medexus Pharmaceuticals Stock Forecast, Price & News

-0.40 (-4.91 %)
(As of 06/16/2021)
Today's Range
50-Day Range
52-Week Range
Volume40,981 shs
Average Volume68,619 shs
Market CapitalizationC$148.54 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.83 out of 5 stars

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Medexus Pharmaceuticals (CVE:MDP) Frequently Asked Questions

Is Medexus Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medexus Pharmaceuticals stock.
View analyst ratings for Medexus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Medexus Pharmaceuticals?

Wall Street analysts have given Medexus Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medexus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Medexus Pharmaceuticals' next earnings date?

Medexus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Medexus Pharmaceuticals

How has Medexus Pharmaceuticals' stock been impacted by COVID-19?

Medexus Pharmaceuticals' stock was trading at C$3.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MDP stock has increased by 158.3% and is now trading at C$7.75.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MDP?

2 brokerages have issued 1-year target prices for Medexus Pharmaceuticals' stock. Their forecasts range from C$9.00 to C$9.00. On average, they expect Medexus Pharmaceuticals' stock price to reach C$9.00 in the next year. This suggests a possible upside of 16.1% from the stock's current price.
View analysts' price targets for Medexus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Medexus Pharmaceuticals' key executives?

Medexus Pharmaceuticals' management team includes the following people:
  • Mr. Kenneth d'Entremont, CEO & Director
  • Mr. Roland Boivin, Chief Financial Officer
  • Mr. Bill Poncy, Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters, VP of Sales & Marketing - United States
  • Ms. Tina Byers CFA, Exec. of Investor Relations
  • Mr. Michael Pine, Sr. VP of Bus. Devel. & Strategy
  • Mr. Michael David Adelman, Gen. Mang., U.S. Operations (Age 50)

Who are some of Medexus Pharmaceuticals' key competitors?

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), (ATE) and Ag Growth International (AFN).

What is Medexus Pharmaceuticals' stock symbol?

Medexus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MDP."

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medexus Pharmaceuticals' stock price today?

One share of MDP stock can currently be purchased for approximately C$7.75.

How much money does Medexus Pharmaceuticals make?

Medexus Pharmaceuticals has a market capitalization of C$148.54 million and generates C$108.29 million in revenue each year.

What is Medexus Pharmaceuticals' official website?

The official website for Medexus Pharmaceuticals is

How can I contact Medexus Pharmaceuticals?

The company can be reached via phone at 514-762-2626.

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.